R&D
Focus Areas Pipeline
PluraStem™ ImmuStem™ MesoStem™ AlloGraf™ GlucoStem™ MorphoGel™ FibroStem™ Neurox™ OsteoStem™ Intellectual Property PublicationsNeurox™
Escape's formulation will be positioned as a premium product under the brand Neurox™ for treatment of muscular spasticity and wrinkle reduction. Attributes of our target formulation include: 1) longer duration of effect, 2) increased potency with a lower effective dose, 3) increased safety and improved side effect profile, and 4) reduced rate of immunogenicity. With an improved therapeutic index relative to Botox, Neurox will represent a significant advancement as a treatment option for patients suffering from a variety of neuromuscular-related chronic diseases shown in the below table.
| Indication | Cases in US |
|---|---|
| Congenital torticollis | 80,000 |
| Cervical dystonia | 165,000 |
| Strabismus | 160,000 |
| Blepharospasm | 25,000 |
| Hyperhidrosis | 3,000,000 |
| Chronic spinal cord injury | 253,000 |
| Acute spinal cord injury | 12,000 |
| spasticity | 3,400,000 |
| Total patients in US | 7,095,000 |
An initial pilot study was completed at Stanford University and its results published in the prestigious Dermatologic Surgery journal in 2007 . Escape is currently conducting additional preclinical animal studies to optimize the Neurox™ formulation and to further strengthen and expand its intellectual property position.
